Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px
Document › Details

ProBioGen AG. (5/5/09). "Press Release: Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with ProBioGen to Explore Production of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX Cell Line". Oxford, Rockville, MD & Berlin.

Organisation Organisation ProBioGen AG
  Group Minapharm (Group)
Product Product  AGE1.CR duck cell line
Person Person Schlenk, Michael (Curasan 201410– Executive Board Director before Centogene + ProBioGen)
     


MVA85A is the most clinically advanced of a new generation of TB vaccines under development


The Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS), announced today the signing of a commercial license agreement with ProBioGen, to evaluate large scale commercial production capabilities for MVA85A, the Consortium’s promising new TB vaccine candidate.

Under the commercial agreement, the Consortium will explore production of MVA85A using the ProBioGen proprietary AGE1.CR.pIX® cell line, which was developed to replace chicken embryonic fibroblasts (CEF) and chicken eggs as production substrates for vaccines.

“We are pleased that the Oxford-Emergent Tuberculosis Consortium is able to work with ProBioGen to evaluate production of MVA85A, the most clinically advanced TB vaccine candidate,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “This agreement represents a step forward in addressing an unmet medical need and is a sign of progress that supports our company mission – to protect life.”

“ProBioGen is well positioned to provide the Oxford-Emergent Tuberculosis Consortium an innovative solution to produce their MVA-based, clinically advanced vaccine” said Michael Schlenk, chief executive officer of ProBioGen. “Our proprietary AGE1.CR.pIX® cell line that we have developed in cooperation with our partner IDT Biologics is a new state-of-the-art technology that provides outstanding productivity and the highest level of characterization.”

The Consortium recently announced the commencement of a Phase IIb clinical trial to evaluate MVA85A in approximately 2,784 children less than one year of age in South Africa. It is expected that the trial will generate important safety, immunogenicity and preliminary efficacy data about the vaccine candidate.

The commercial license includes an upfront payment to ProBioGen as well as development milestone payments and royalties on future sales of the TB candidate.

   
Record changed: 2016-03-20

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Minapharm (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wptb




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px